Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients

[1]  F. Gaita,et al.  HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. , 2016, Progress in cardiovascular diseases.

[2]  L. Calza,et al.  No correlation between statin exposure and incident diabetes mellitus in HIV‐1‐infected patients receiving combination antiretroviral therapy , 2016, HIV medicine.

[3]  D. Betteridge,et al.  The diabetogenic action of statins — mechanisms and clinical implications , 2016, Nature Reviews Endocrinology.

[4]  G. McComsey,et al.  Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Lichtenstein,et al.  Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study , 2015, Journal of acquired immune deficiency syndromes.

[6]  Jennifer G. Robinson.  Statins and diabetes risk: how real is it and what are the mechanisms? , 2015, The Medical letter on drugs and therapeutics.

[7]  K. Kraemer,et al.  HIV status and the risk of ischemic stroke among men , 2015, Neurology.

[8]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[9]  A. Lazzarin,et al.  Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy , 2014, AIDS.

[10]  Tara Gomes,et al.  Risk of incident diabetes among patients treated with statins: population based study , 2013, BMJ.

[11]  D. Kitch,et al.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  K. Kraemer,et al.  HIV infection and the risk of acute myocardial infarction. , 2013, JAMA internal medicine.

[13]  C. Larsen,et al.  Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study , 2013, PloS one.

[14]  P. Sax,et al.  Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. , 2012, AIDS research and human retroviruses.

[15]  A. Lazzarin,et al.  Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy , 2012, European Journal of Epidemiology.

[16]  J. Capeau,et al.  Effects of Ritonavir-Boosted Darunavir, Atazanavir and Lopinavir on Adipose Functions and Insulin Sensitivity in Murine and Human Adipocytes , 2012, Antiviral therapy.

[17]  C. Katlama,et al.  Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment , 2012, AIDS.

[18]  M. Horberg,et al.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons , 2011, AIDS.

[19]  Richard D Moore,et al.  Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients , 2011, PloS one.

[20]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[21]  K. Alberti,et al.  The classification and diagnosis of diabetes mellitus. , 2010, The New Zealand medical journal.

[22]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[23]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[24]  Lijie Zhong,et al.  The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers , 2010, Antiviral therapy.

[25]  K. Samaras.  Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. , 2009, Journal of acquired immune deficiency syndromes.

[26]  J. Aberg.  Cardiovascular Complications in HIV Management: Past, Present, and Future , 2009, Journal of acquired immune deficiency syndromes.

[27]  Nina Friis-Møller,et al.  Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients , 2008, Diabetes Care.

[28]  D. Margolis,et al.  Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male Patients After Switch to Atazanavir/Ritonavir , 2008, Journal of Investigative Medicine.

[29]  M. Egger,et al.  Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Stephen R Cole,et al.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. , 2005, Archives of internal medicine.

[31]  Jack Wang,et al.  Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine , 2005, Journal of acquired immune deficiency syndromes.

[32]  K. Yarasheski,et al.  Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.

[33]  A. Lazzarin,et al.  Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals , 2003, AIDS.

[34]  Richard D Moore,et al.  The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV‐Infected Persons , 2003, Journal of acquired immune deficiency syndromes.

[35]  M. Schambelan,et al.  Altered Fat Distribution in HIV‐Positive Men on Nucleoside Analog Reverse Transcriptase Inhibitor Therapy , 2001, Journal of acquired immune deficiency syndromes.

[36]  C. Moore,et al.  Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection , 2000, AIDS.

[37]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[38]  S. Genuth,et al.  Classification and diagnosis of diabetes mellitus. , 1982, The Medical clinics of North America.

[39]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .